JP2021527651A5 - - Google Patents

Info

Publication number
JP2021527651A5
JP2021527651A5 JP2020570030A JP2020570030A JP2021527651A5 JP 2021527651 A5 JP2021527651 A5 JP 2021527651A5 JP 2020570030 A JP2020570030 A JP 2020570030A JP 2020570030 A JP2020570030 A JP 2020570030A JP 2021527651 A5 JP2021527651 A5 JP 2021527651A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
sarna
additional activator
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020570030A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021527651A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/GB2019/051654 external-priority patent/WO2019239144A1/en
Publication of JP2021527651A publication Critical patent/JP2021527651A/ja
Publication of JP2021527651A5 publication Critical patent/JP2021527651A5/ja
Priority to JP2024087660A priority Critical patent/JP2024103632A/ja
Pending legal-status Critical Current

Links

JP2020570030A 2018-06-15 2019-06-14 Ｃ／ＥＢＰアルファｓａＲＮＡを含む併用療法 Pending JP2021527651A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024087660A JP2024103632A (ja) 2018-06-15 2024-05-30 Ｃ／ＥＢＰアルファｓａＲＮＡを含む併用療法

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862685627P 2018-06-15 2018-06-15
US62/685,627 2018-06-15
US201862731532P 2018-09-14 2018-09-14
US62/731,532 2018-09-14
US201962821533P 2019-03-21 2019-03-21
US62/821,533 2019-03-21
PCT/GB2019/051654 WO2019239144A1 (en) 2018-06-15 2019-06-14 Combination therapies comprising c/ebp alpha sarna

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024087660A Division JP2024103632A (ja) 2018-06-15 2024-05-30 Ｃ／ＥＢＰアルファｓａＲＮＡを含む併用療法

Publications (2)

Publication Number Publication Date
JP2021527651A JP2021527651A (ja) 2021-10-14
JP2021527651A5 true JP2021527651A5 (enExample) 2022-06-20

Family

ID=67070873

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020570030A Pending JP2021527651A (ja) 2018-06-15 2019-06-14 Ｃ／ＥＢＰアルファｓａＲＮＡを含む併用療法
JP2024087660A Withdrawn JP2024103632A (ja) 2018-06-15 2024-05-30 Ｃ／ＥＢＰアルファｓａＲＮＡを含む併用療法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024087660A Withdrawn JP2024103632A (ja) 2018-06-15 2024-05-30 Ｃ／ＥＢＰアルファｓａＲＮＡを含む併用療法

Country Status (7)

Country Link
US (1) US20210254069A1 (enExample)
EP (1) EP3807410A1 (enExample)
JP (2) JP2021527651A (enExample)
CN (1) CN112543809A (enExample)
AU (1) AU2019285344A1 (enExample)
CA (1) CA3102334A1 (enExample)
WO (1) WO2019239144A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4013878A1 (en) * 2019-08-14 2022-06-22 Codiak BioSciences, Inc. Extracellular vesicle-aso constructs targeting cebp/beta
IL328607A (en) * 2020-05-12 2026-07-01 Astrazeneca Ab Methods and combinations for treating cancer using immune checkpoint inhibitor antibodies
CN111876390B (zh) * 2020-08-12 2021-04-09 湖南南华爱世普林生物技术有限公司 负载化合物的转基因干细胞外泌体在制备药物或美白化妆品中的用途
WO2022229644A1 (en) * 2021-04-28 2022-11-03 Mina Therapeutics Limited Combination therapies comprising c/ebp alpha sarna
CN114306367B (zh) * 2021-08-27 2023-03-28 赵小洋 一种含有C/EBPα-saRNA的组合物
WO2024175887A1 (en) * 2023-02-22 2024-08-29 Mina Therapeutics Limited Compositions and methods of using c/ebp alpha sarna

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5851795A (en) 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
EP0970128A1 (en) 1997-03-21 2000-01-12 Brigham And Women's Hospital Immunotherapeutic ctla-4 binding peptides
AU5613999A (en) 1998-09-18 2000-04-10 University Of British Columbia, The Pharmaceutical compositions of vanadium biguanide complexes and their use
US7109003B2 (en) 1998-12-23 2006-09-19 Abgenix, Inc. Methods for expressing and recovering human monoclonal antibodies to CTLA-4
US6682736B1 (en) 1998-12-23 2004-01-27 Abgenix, Inc. Human monoclonal antibodies to CTLA-4
EP1854880A1 (en) 1999-03-15 2007-11-14 University of British Columbia Methods and reagents for modulating cholesterol levels
NZ517202A (en) 1999-08-24 2004-05-28 Medarex Inc Human CTLA-4 antibodies and their uses
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
AU2001233027A1 (en) 2000-01-27 2001-08-07 Genetics Institute, Llc Antibodies against ctla4 (cd152), conjugates comprising same, and uses thereof
KR100944575B1 (ko) 2002-10-17 2010-02-25 젠맵 에이/에스 Ｃｄ20에 대한 인간 모노클로날 항체
US7465446B2 (en) 2003-05-30 2008-12-16 Medarex, Inc. Surrogate therapeutic endpoint for anti-CTLA4-based immunotherapy of disease
JP5362350B2 (ja) 2005-04-15 2013-12-11 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 小分子活性化ｒｎａ分子及び使用方法
CA2629664A1 (en) 2005-11-17 2007-08-02 Board Of Regents, The University Of Texas System Modulation of gene expression by oligomers targeted to chromosomal dna
US8748815B2 (en) 2006-08-31 2014-06-10 Hermes Microvision, Inc. Method and system for detecting or reviewing open contacts on a semiconductor device
EP1918376A1 (en) * 2006-11-03 2008-05-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. FGFR4 promotes cancer cell resistance in response to chemotherapeutic drugs
EP2086644A2 (en) * 2006-11-17 2009-08-12 Schering Corporation Combination of an inhibitor of dna polymerase-alpha and an inhibitor of a checkpoint kinase for proliferative disorders
WO2010124231A2 (en) 2009-04-24 2010-10-28 The Board Of Regents Of The University Of Texas System Modulation of gene expression using oligomers that target gene regions downstream of 3' untranslated regions
CN101941001B (zh) 2009-07-03 2014-04-02 3M创新有限公司 亲水涂层、制品、涂料组合物和方法
WO2011069529A1 (en) 2009-12-09 2011-06-16 Curevac Gmbh Mannose-containing solution for lyophilization, transfection and/or injection of nucleic acids
CA2817191A1 (en) 2010-10-08 2012-04-12 Pal Saetrom Short rna molecules
WO2012175958A1 (en) 2011-06-21 2012-12-27 Mina Therapeutics Limited Albumin production and cell proliferation
ES2923757T3 (es) 2011-12-16 2022-09-30 Modernatx Inc Composiciones de ARNm modificado
SI3071696T1 (sl) * 2013-11-22 2019-11-29 Mina Therapeutics Ltd C/EBP alfa kratko delujoči RNA sestavki in postopki uporabe
CN108291228A (zh) * 2015-04-22 2018-07-17 米纳治疗有限公司 C/EBPαSARNA组合物和使用方法
US10995143B2 (en) * 2016-02-10 2021-05-04 Daiichi Sankyo Europe Gmbh Combination of human anti-FGFR4 antibody and Sorafenib
CN110022900A (zh) * 2016-09-08 2019-07-16 蓝图药品公司 成纤维细胞生长因子受体4抑制剂与细胞周期蛋白依赖性激酶抑制剂的组合

Similar Documents

Publication Publication Date Title
Kružliak et al. Vascular endothelial growth factor inhibitor–induced hypertension: from pathophysiology to prevention and treatment based on long-acting nitric oxide donors
Ellis et al. Bevacizumab
Grønhøj et al. Beneficial potential of intravenously administered IL-6 in improving outcome after murine experimental stroke
JP2018536689A5 (enExample)
SG10201903290YA (en) Modified double-stranded rna agents
JP2017537070A5 (enExample)
KR20170139055A (ko) 백금계 항암제에 의해 유도된 세포 내 증가된 p53 수준을 유지시키는 방법 및 이의 활용
JP2012505660A5 (enExample)
Chakravarthy et al. Nerve growth factor (NGF)-mediated regulation of p75NTR expression contributes to chemotherapeutic resistance in triple negative breast cancer cells
RU2017120536A (ru) Способы и композиции для модулирования экспрессии аполипопротеина (а)
JP2019506862A5 (enExample)
RU2021130306A (ru) Композиции il-12, нацеленные на edb
Qian et al. Identification of nicotinic acetylcholine receptor subunits in different lung cancer cell lines and the inhibitory effect of alpha-conotoxin TxID on lung cancer cell growth
JP2019512543A5 (enExample)
JP2017536408A5 (enExample)
JP2020537695A (ja) ストレプトニグリンおよびラパマイシンを有効成分として含む、癌の予防または治療用薬学的組成物
Zhou et al. Long noncoding RNA ZFAS1 promotes hepatocellular carcinoma proliferation by epigenetically repressing miR-193a-3p.
Kelly et al. Chemotherapy in metastatic colorectal cancer
JP2024502615A5 (enExample)
Du et al. Kaempferide enhances type I interferon signaling as a novel broad-spectrum antiviral agent
JP2019504860A5 (enExample)
Naeim et al. A phase II trial of frontline capecitabine and bevacizumab in poor performance status and/or elderly patients with metastatic colorectal cancer
CN102816792B (zh) 一种调控热休克蛋白70表达、数量及活性的方法及其应用
JP2021500026A5 (enExample)
Tong et al. Recombinant nematode anticoagulant protein c2 inhibits cell invasion by decreasing uPA expression in NSCLC cells